Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $345,000.

  • 4D Molecular Therapeutics' Other Non-Current Liabilities fell 12.88% to $345,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $345,000, marking a year-over-year decrease of 12.88%. This contributed to the annual value of $410,000 for FY2024, which is 11.11% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Other Non-Current Liabilities stood at $345,000, which was up 3.29% from $334,000 recorded in Q2 2025.
  • 4D Molecular Therapeutics' Other Non-Current Liabilities' 5-year high stood at $1.9 million during Q3 2021, with a 5-year trough of $212,000 in Q4 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $369,000 (2024), whereas its average is $338,818.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Other Non-Current Liabilities slumped by 88.71% in 2022 and then soared by 80.19% in 2024.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Other Non-Current Liabilities stood at $214,000 in 2021, then decreased by 0.93% to $212,000 in 2022, then spiked by 74.06% to $369,000 in 2023, then rose by 11.11% to $410,000 in 2024, then fell by 12.88% to $345,000 in 2025.
  • Its Other Non-Current Liabilities was $345,000 in Q3 2025, compared to $334,000 in Q2 2025 and $322,000 in Q1 2025.